Eli Lilly and Company and Incyte Corporation announced that the FDA has approved the 2-mg dose of Olumiant (baricitinib), a...
Eli Lilly and Company will present new data for Olumiant (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020) taking place June 3-6, 2020.
Eli Lilly and Company and Incyte announced that the FDA has approved Olumiant (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.
Through new analyses of BREEZE-AD5 Phase III clinical trial data and an extended safety analysis across multiple trials , Eli Lilly and Company and Incyte's Olumiant (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate to severe atopic dermatitis (AD).
Eli Lilly announced that the FDA has approved Olumiant (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first.
The National Institute for Health and Care Excellence (NICE) in draft guidelines has recommended, JAK inhibitor, Olumiant (baricitinib) from Eli...
Olumiant (baricitinib) from Eli Lilly and Incyte, maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received Olumiant for 14,744 patient years of exposure, in line with previously published findings.
Eli Lilly and Company and Incyte Corporation announced findings from an updated integrated safety analysis of Olumiant (baricitinib) based on...
Eli Lilly and Company and Incyte announced updates on the Phase III development program for Olumiant (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus) and the status of the U.S. atopic dermatitis supplemental new drug application (sNDA).
Eli Lilly and Company and Incyte Corporation announced that the European Commission has granted marketing authorisation for Olumiant (baricitinib) 4...